{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:15:16Z","timestamp":1792178116088,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1149"],"award-info":[{"award-number":["CRC1149"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1506"],"award-info":[{"award-number":["CRC 1506"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Phelan-McDermid syndrome (PMS) is a relatively frequent cause of syndromic intellectual disability (ID) and autism spectrum disorder (ASD). It is typically caused by genetic alterations in the 22q13 chromosomal region, most often involving heterozygous deletions or mutations in the\n                    <jats:italic>SHANK3<\/jats:italic>\n                    gene. More than half of affected individuals exhibit functional impairments in speech, cognition, motor skills, and behavior. Despite multiple ongoing therapeutic programs, objective and scalable liquid biomarkers to support patient stratification and to monitor disease course or treatment response are still lacking. Here, in a pilot study involving 23 individuals with PMS, we identified two biomarkers that are significantly altered compared to a control group and are associated with symptom severity. First, SHANK3 protein was detectable in peripheral blood mononuclear cells (PBMCs) and was markedly reduced in PMS (mean \u221277% vs. controls), consistent with SHANK3 haploinsufficiency; lower PBMC SHANK3 levels were associated with the presence of developmental regression, supporting its potential utility as a target-engagement\/monitoring biomarker rather than a diagnostic screen. Additionally, plasma levels of beta-synuclein, a neuron-specific synaptic protein, were elevated in PMS and positively correlated with the severity of speech impairment. Both biomarkers were successfully back-translated in a\n                    <jats:italic>Shank3<\/jats:italic>\n                    transgenic mouse model, where beta-synuclein levels were normalized through modulation of the mGlu5 receptor. Together, these results provide initial evidence for SHANK3 in PBMCs and plasma beta-synuclein as complementary liquid biomarkers to aid prognosis and enable objective monitoring of therapeutic response in PMS, warranting validation in larger and pediatric longitudinal cohorts.\n                  <\/jats:p>","DOI":"10.1038\/s41398-026-03932-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:55:22Z","timestamp":1774346122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SHANK3 and beta-synuclein are novel blood-based biomarkers for the Phelan-McDermid Syndrome: a pilot study"],"prefix":"10.1038","volume":"16","author":[{"given":"Jessica","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Perez Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Nosanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7483-137X","authenticated-orcid":false,"given":"Helen Friedericke","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Loth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-4267","authenticated-orcid":false,"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7597-7912","authenticated-orcid":false,"given":"Alessia","family":"Stefanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-9725","authenticated-orcid":false,"given":"Chiara","family":"Verpelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-8535","authenticated-orcid":false,"given":"Tobias","family":"Boeckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3932_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000334260","volume":"2","author":"K Phelan","year":"2012","unstructured":"Phelan K, McDermid HE. The 22q13.3 deletion syndrome (Phelan-McDermid syndrome). Mol Syndromol. 2012;2:186\u2013201.","journal-title":"Mol Syndromol"},{"key":"3932_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/1096-8628(20010615)101:2<91::AID-AJMG1340>3.0.CO;2-C","volume":"101","author":"MC Phelan","year":"2001","unstructured":"Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, McDermid H, et al. 22q13 deletion syndrome. Am J Med Genet. 2001;101:91\u20139.","journal-title":"Am J Med Genet"},{"key":"3932_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000339119","volume":"3","author":"A Denayer","year":"2012","unstructured":"Denayer A, Van Esch H, de Ravel T, Frijns JP, Van Buggenhout G, Vogels A, et al. Neuropsychopathology in 7 patients with the 22q13 deletion syndrome: presence of bipolar disorder and progressive loss of skills. Mol Syndromol. 2012;3:14\u201320.","journal-title":"Mol Syndromol"},{"key":"3932_CR4","doi-asserted-by":"publisher","first-page":"104732","DOI":"10.1016\/j.ejmg.2023.104732","volume":"66","author":"A Vitrac","year":"2023","unstructured":"Vitrac A, Leblond CS, Rolland T, Cliquet F, Mathieu A, Maruani A, et al. Dissecting the 22q13 region to explore the genetic and phenotypic diversity of patients with Phelan-McDermid syndrome. Eur J Med Genet. 2023;66:104732.","journal-title":"Eur J Med Genet"},{"key":"3932_CR5","doi-asserted-by":"publisher","first-page":"104773","DOI":"10.1016\/j.ejmg.2023.104773","volume":"66","author":"SA Koza","year":"2023","unstructured":"Koza SA, Tabet AC, Bonaglia MC, Andres S, Anderlid BM, Aten E, et al. Consensus recommendations on counselling in Phelan-McDermid syndrome, with special attention to recurrence risk and to ring chromosome 22. Eur J Med Genet. 2023;66:104773.","journal-title":"Eur J Med Genet"},{"key":"3932_CR6","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ajmg.a.36513","volume":"164A","author":"V Disciglio","year":"2014","unstructured":"Disciglio V, Lo Rizzo C, Mencarelli MA, Mucciolo M, Marozza A, Di Marco C, et al. Interstitial 22q13 deletions not involving SHANK3 gene: a new contiguous gene syndrome. Am J Med Genet A. 2014;164A:1666\u201376.","journal-title":"Am J Med Genet A"},{"key":"3932_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajmg.a.36358","volume":"164","author":"K Simenson","year":"2014","unstructured":"Simenson K, \u00d5iglane-Shlik E, Teek R, Kuuse K, \u00d5unap K. A patient with the classic features of Phelan-McDermid syndrome and a high immunoglobulin E level caused by a cryptic interstitial 0.72-Mb deletion in the 22q13.2 region. Am J Med Genet A. 2014;164:806\u20139.","journal-title":"Am J Med Genet A"},{"key":"3932_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-020-00802-0","volume":"13","author":"S Li","year":"2020","unstructured":"Li S, Xi KW, Liu T, Zhang Y, Zhang M, Zeng LD, et al. Fraternal twins with Phelan-McDermid syndrome not involving the SHANK3 gene: case report and literature review. BMC Med Genomics. 2020;13:146.","journal-title":"BMC Med Genomics"},{"key":"3932_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/ejhg.2008.107","volume":"16","author":"HL Wilson","year":"2008","unstructured":"Wilson HL, Crolla JA, Walker D, Artifoni L, Dallapiccola B, Takano T, et al. Interstitial 22q13 deletions: genes other than SHANK3 have major effects on cognitive and language development. Eur J Hum Genet. 2008;16:1301\u201310.","journal-title":"Eur J Hum Genet"},{"key":"3932_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02180-5","volume":"17","author":"K Phelan","year":"2022","unstructured":"Phelan K, Boccuto L, Powell CM, Boeckers TM, van Ravenswaaij-Arts C, Rogers RC, et al. Phelan-McDermid syndrome: a classification system after 30 years of experience. Orphanet J Rare Dis. 2022;17:27.","journal-title":"Orphanet J Rare Dis"},{"key":"3932_CR11","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1523\/JNEUROSCI.4354-04.2005","volume":"25","author":"G Roussignol","year":"2005","unstructured":"Roussignol G, Ango F, Romorini S, Tu JC, Sala C, Worley PF, et al. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci. 2005;25:3560\u201370.","journal-title":"J Neurosci"},{"key":"3932_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/jnc.13232","volume":"135","author":"C Sala","year":"2015","unstructured":"Sala C, Vicidomini C, Bigi I, Mossa A, Verpelli C. Shank synaptic scaffold proteins: keys to understanding the pathogenesis of autism and other synaptic disorders. J Neurochem. 2015;135:849\u201358.","journal-title":"J Neurochem"},{"key":"3932_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1242\/jcs.113.11.1851","volume":"113","author":"M Sheng","year":"2000","unstructured":"Sheng M, Kim E. The Shank family of scaffold proteins. J Cell Sci. 2000;113:1851\u201356.","journal-title":"J Cell Sci"},{"key":"3932_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00018-022-04400-4","volume":"79","author":"M Malara","year":"2022","unstructured":"Malara M, Lutz AK, Incearap B, Bauer HF, Cursano S, Volbracht K, et al. SHANK3 deficiency leads to myelin defects in the central and peripheral nervous system. Cell Mol Life Sci. 2022;79:371.","journal-title":"Cell Mol Life Sci"},{"key":"3932_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/acn3.50959","volume":"7","author":"S Jesse","year":"2020","unstructured":"Jesse S, M\u00fcller HP, Schoen M, Asoglu H, Bockmann J, Huppertz HJ, et al. Severe white matter damage in SHANK3 deficiency: a human and translational study. Ann Clin Transl Neurol. 2020;7:46\u201358.","journal-title":"Ann Clin Transl Neurol"},{"key":"3932_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng1933","volume":"39","author":"CM Durand","year":"2007","unstructured":"Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39:25\u20137.","journal-title":"Nat Genet"},{"key":"3932_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/mp.2011.57","volume":"17","author":"CM Durand","year":"2012","unstructured":"Durand CM, Perroy J, Loll F, Perrais D, Fagni L, Bourgeron T, et al. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry. 2012;17:71\u201384.","journal-title":"Mol Psychiatry"},{"key":"3932_CR18","doi-asserted-by":"publisher","first-page":"e1004580","DOI":"10.1371\/journal.pgen.1004580","volume":"10","author":"CS Leblond","year":"2014","unstructured":"Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, Lumbroso S, et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 2014;10:e1004580.","journal-title":"PLoS Genet"},{"key":"3932_CR19","doi-asserted-by":"publisher","first-page":"104754","DOI":"10.1016\/j.ejmg.2023.104754","volume":"66","author":"M Sch\u00f6n","year":"2023","unstructured":"Sch\u00f6n M, Lapunzina P, Nevado J, Mattina T, Gunnarsson C, Hadzsiev K, et al. Definition and clinical variability of SHANK3-related Phelan-McDermid syndrome. Eur J Med Genet. 2023;66:104754.","journal-title":"Eur J Med Genet"},{"key":"3932_CR20","doi-asserted-by":"publisher","first-page":"1051175","DOI":"10.3389\/fnbeh.2022.1051175","volume":"16","author":"HF Bauer","year":"2022","unstructured":"Bauer HF, Delling JP, Bockmann J, Boeckers TM, Sch\u00f6n M. Development of sex- and genotype-specific behavioral phenotypes in a Shank3 mouse model for neurodevelopmental disorders. Front Behav Neurosci. 2022;16:1051175.","journal-title":"Front Behav Neurosci"},{"key":"3932_CR21","doi-asserted-by":"publisher","first-page":"e70146","DOI":"10.1002\/alz.70146","volume":"21","author":"P Oeckl","year":"2025","unstructured":"Oeckl P, Mayer B, Bateman RJ, Day GS, Fox NC, Huey ED, et al. Early increase of the synaptic blood marker \u03b2-synuclein in asymptomatic autosomal dominant Alzheimer\u2019s disease. Alzheimers Dement. 2025;21:e70146.","journal-title":"Alzheimers Dement"},{"key":"3932_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","volume":"19","author":"P Oeckl","year":"2020","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, von Arnim CAF, Diehl-Schmid J, Froelich L, et al. Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer\u2019s disease. J Proteome Res. 2020;19:1310\u20138.","journal-title":"J Proteome Res"},{"key":"3932_CR23","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1002\/alz.13103","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, et al. Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:5095\u2013102.","journal-title":"Alzheimers Dement"},{"key":"3932_CR24","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12790","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, et al. Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement. 2023;19:1358\u201371.","journal-title":"Alzheimers Dement"},{"key":"3932_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/jnnp-2022-329124","volume":"94","author":"L Barba","year":"2023","unstructured":"Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, et al. Cerebrospinal fluid \u03b2-synuclein as a synaptic biomarker for preclinical Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2023;94:83\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3932_CR26","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1038\/s41380-025-02947-9","volume":"30","author":"F Giona","year":"2025","unstructured":"Giona F, Beretta S, Zippo A, Stefanoni A, Tomasoni Z, Vicidomini C, et al. Shank3 modulates Rpl3 expression and protein synthesis via mGlu5: implications for Phelan McDermid syndrome. Mol Psychiatry. 2025;30:3599\u2013614. https:\/\/doi.org\/10.1038\/s41380-025-02947-9.","journal-title":"Mol Psychiatry"},{"key":"3932_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/mp.2016.30","volume":"22","author":"C Vicidomini","year":"2017","unstructured":"Vicidomini C, Ponzoni L, Lim D, Schmeisser MJ, Reim D, Morello N, et al. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice. Mol Psychiatry. 2017;22:689\u2013702.","journal-title":"Mol Psychiatry"},{"key":"3932_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/genes13030504","volume":"13","author":"F Cammarata-Scalisi","year":"2022","unstructured":"Cammarata-Scalisi F, Callea M, Martinelli D, Willoughby CE, C\u00e1rdenas Tadich A, Araya Castillo M, et al. Clinical and genetic aspects of Phelan-McDermid syndrome: an interdisciplinary approach to management. Genes. 2022;13:504.","journal-title":"Genes"},{"key":"3932_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.semperi.2014.10.009","volume":"39","author":"DG Peters","year":"2015","unstructured":"Peters DG, Yatsenko SA, Surti U, Rajkovic A. Recent advances of genomic testing in perinatal medicine. Semin Perinatol. 2015;39:44\u201354.","journal-title":"Semin Perinatol"},{"key":"3932_CR30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2014.02.002","volume":"156","author":"HA Stessman","year":"2014","unstructured":"Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014;156:872\u201377.","journal-title":"Cell"},{"key":"3932_CR31","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaac.2012.08.018","volume":"51","author":"G Dawson","year":"2012","unstructured":"Dawson G, Jones EJH, Merkle K, Venema K, Lowy R, Faja S, et al. Early behavioral intervention is associated with normalized brain activity in young children with autism. J Am Acad Child Adolesc Psychiatry. 2012;51:1150\u201359.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3932_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrd.2015.7","volume":"15","author":"E Loth","year":"2016","unstructured":"Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, et al. Identification and validation of biomarkers for autism spectrum disorders. Nat Rev Drug Discov. 2016;15:70\u20133.","journal-title":"Nat Rev Drug Discov"},{"key":"3932_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2020.616641","volume":"14","author":"M Sahin","year":"2020","unstructured":"Sahin M, Sweeney JA, Jones SR. Editorial: biomarkers to enable therapeutics development in neurodevelopmental disorders. Front Integr Neurosci. 2020;14:616641.","journal-title":"Front Integr Neurosci"},{"key":"3932_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ajmg.b.30272","volume":"141B","author":"PF Sullivan","year":"2006","unstructured":"Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:261\u201368.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"3932_CR35","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ajmg.b.31062","volume":"153B","author":"B Rollins","year":"2010","unstructured":"Rollins B, Martin MV, Morgan L, Vawter MP. Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:919\u201336.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"3932_CR36","doi-asserted-by":"publisher","first-page":"e25545","DOI":"10.1371\/journal.pone.0025545","volume":"6","author":"G Nardo","year":"2011","unstructured":"Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6:e25545.","journal-title":"PLoS One"},{"key":"3932_CR37","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3390\/ijms23052580","volume":"23","author":"O Pansarasa","year":"2022","unstructured":"Pansarasa O, Garofalo M, Scarian E, Dragoni F, Garau J, Di Gerlando R, et al. Biomarkers in human peripheral blood mononuclear cells: the state of the art in amyotrophic lateral sclerosis. Int J Mol Sci. 2022;23:2580.","journal-title":"Int J Mol Sci"},{"key":"3932_CR38","doi-asserted-by":"crossref","unstructured":"Kleiveland CR Peripheral blood mononuclear cells. In: Verhoeckx K, Cotter P, L\u00f3pez-Exp\u00f3sito I, Kleiveland C, Lea T, Mackie A et al. eds. The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Cham: Springer, 2015:pp. 161\u201367.","DOI":"10.1007\/978-3-319-16104-4_15"},{"key":"3932_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00418-006-0199-9","volume":"126","author":"P Redecker","year":"2006","unstructured":"Redecker P, Bockmann J, B\u00f6ckers TM. Expression of postsynaptic density proteins of the ProSAP\/Shank family in the thymus. Histochem Cell Biol. 2006;126:679\u201385.","journal-title":"Histochem Cell Biol"},{"key":"3932_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-018-0205-9","volume":"9","author":"S De Rubeis","year":"2018","unstructured":"De Rubeis S, Siper PM, Durkin A, Weissman J, Muratet F, Halpern D, et al. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations. Mol Autism. 2018;9:31.","journal-title":"Mol Autism"},{"key":"3932_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ajmg.a.33253","volume":"152A","author":"SU Dhar","year":"2010","unstructured":"Dhar SU, del Gaudio D, German JR, Peters SU, Ou Z, Bader PI, et al. 22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A. 2010;152A:573\u201381.","journal-title":"Am J Med Genet A"},{"key":"3932_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s11689-019-9273-1","volume":"11","author":"CI Samogy-Costa","year":"2019","unstructured":"Samogy-Costa CI, Varella-Branco E, Monfardini F, Ferraz H, Fock RA, Barbosa RHA, et al. A Brazilian cohort of individuals with Phelan-McDermid syndrome: genotype-phenotype correlation and identification of an atypical case. J Neurodev Disord. 2019;11:13.","journal-title":"J Neurodev Disord"},{"key":"3932_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01592-5","volume":"15","author":"N Xu","year":"2020","unstructured":"Xu N, Lv H, Yang T, Du X, Sun Y, Xiao B, et al. A 29 Mainland Chinese cohort of patients with Phelan-McDermid syndrome: genotype-phenotype correlations and the role of SHANK3 haploinsufficiency in the important phenotypes. Orphanet J Rare Dis. 2020;15:335.","journal-title":"Orphanet J Rare Dis"},{"key":"3932_CR44","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/13854046.2017.1413211","volume":"32","author":"L Soorya","year":"2018","unstructured":"Soorya L, Leon J, Trelles MP, Thurm A. Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid syndrome. Clin Neuropsychol. 2018;32:1226\u201355.","journal-title":"Clin Neuropsychol"},{"key":"3932_CR45","first-page":"100145","volume":"4","author":"MS Breen","year":"2022","unstructured":"Breen MS, Fan X, Levy T, Pollak RM, Collins B, Osman A, et al. Large 22q13.3 deletions perturb peripheral transcriptomic and metabolomic profiles in Phelan-McDermid syndrome. HGG Adv. 2022;4:100145.","journal-title":"HGG Adv"},{"key":"3932_CR46","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","volume":"15","author":"P Oeckl","year":"2016","unstructured":"Oeckl P, Metzger F, Nagl M, von Arnim CAF, Halbgebauer S, Steinacker P, et al. Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer\u2019s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol Cell Proteom. 2016;15:3126\u201338.","journal-title":"Mol Cell Proteom"},{"key":"3932_CR47","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/acn3.51402","volume":"8","author":"S Bergstr\u00f6m","year":"2021","unstructured":"Bergstr\u00f6m S, Remnest\u00e5l J, Yousef J, Olofsson J, Markaki I, Carvalho S, et al. Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2021;8:1456\u201370.","journal-title":"Ann Clin Transl Neurol"},{"key":"3932_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/jnnp-2020-324306","volume":"92","author":"S Halbgebauer","year":"2021","unstructured":"Halbgebauer S, Oeckl P, Steinacker P, Yilmazer-Hanke D, Anderl-Straub S, von Arnim C, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2021;92:349\u201356.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3932_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jpsychires.2017.03.010","volume":"91","author":"G Reierson","year":"2017","unstructured":"Reierson G, Bernstein J, Froehlich-Santino W, Urban A, Purmann C, Berquist S, et al. Characterizing regression in Phelan McDermid syndrome (22q13 deletion syndrome). J Psychiatr Res. 2017;91:139\u201344.","journal-title":"J Psychiatr Res"},{"key":"3932_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11689-020-9309-6","volume":"12","author":"TM Kohlenberg","year":"2020","unstructured":"Kohlenberg TM, Trelles MP, McLarney B, Betancur C, Thurm A, Kolevzon A. Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. J Neurodev Disord. 2020;12:7.","journal-title":"J Neurodev Disord"},{"key":"3932_CR51","doi-asserted-by":"publisher","first-page":"104736","DOI":"10.1016\/j.ejmg.2023.104736","volume":"66","author":"CMA van Ravenswaaij-Arts","year":"2023","unstructured":"van Ravenswaaij-Arts CMA, van Balkom IDC, Jesse S, Bonaglia MC. Editorial: Towards a European consensus guideline for Phelan-McDermid syndrome. Eur J Med Genet. 2023;66:104736.","journal-title":"Eur J Med Genet"},{"key":"3932_CR52","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/ajmg.a.63312","volume":"191","author":"S Srivastava","year":"2023","unstructured":"Srivastava S, Sahin M, Buxbaum JD, Berry-Kravis E, Soorya LV, Thurm A, et al. Updated consensus guidelines on the management of Phelan-McDermid syndrome. Am J Med Genet A. 2023;191:2015\u201344.","journal-title":"Am J Med Genet A"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03932-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:03:20Z","timestamp":1774969400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03932-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3932"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-03932-8","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PO received consulting fees from LifeArc and Fundamental Pharma and travel support from Biogen. MO and PO are co-inventors of a patent application for using beta-synuclein measurement in blood (EP4014048A1, US2022283184A1). Other than that there is no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}